Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Nom du journal : EBioMedicine
Année : 2024
Volume : 109
Page de départ : 105374
